Who to call at Regeneron, and when

Fundz watches for the moments Regeneron starts buying, and tells you who to reach.

An alert the day Regeneron raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Regeneron, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Regeneron. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Regeneron partners with Parabilis to develop a new class of drug worth up to $2.3 billion.

May 18, 2026

Contract Type

partnership

TarrytownBiotechnologyHealth CareScience And EngineeringTherapeutics

Description

Regeneron is investing $75 million in Parabilis Medicines and committing up to $2.3 billion for a research collaboration aimed at creating a novel drug class called antibody-helicon conjugates (AHCs). By combining Regeneron’s expertise in antibody-drug conjugates with Parabilis’ peptide platform, the partnership seeks to tackle challenging drug targets.

Quick answer

Regeneron partners with Parabilis to develop a new class of drug worth up to $2.3 billion. (May 18, 2026). Regeneron is based in Tarrytown, New York, United States.

What agreement did Regeneron announce on May 18, 2026?: Regeneron is investing $75 million in Parabilis Medicines and committing up to $2.3 billion for a research collaboration aimed at creating a novel drug class called antibody-helicon conjugates (AHCs). By combining Regeneron’s expertise in antibody-drug conjugates with Parabilis’ peptide platform, the partnership seeks to tackle challenging drug targets.
What does Regeneron do?: Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
Where is Regeneron based?: Regeneron is based in Tarrytown, New York, United States.

Source: Fundz verified event record.

Company Information

Company

Regeneron

Location

777 Old Saw Mill River Road

Tarrytown, New York, United States

About

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Predictive Intelligence

Strategic

ML-powered predictions for Regeneron's next move

Learn about Strategic plan

Agreement Insights

What this usually means

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Regeneron signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a services firm uses this Or see plans and pricing →

5 screens from a live account. No signup.